IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today.



Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in advanced ovarian cancer, and the oncological space – and ASCO 2025 itself – more generally.



You can also listen to episode 185a of the pharmaphorum podcast  (https://pharmaphorum.com/podcasts) in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts (https://podcasts.apple.com/gb/podcast/pharmaphorum-podcast/id1405602673) , Spotify (https://open.spotify.com/show/1wbZ50ISkG1ugucigybcYf) , Overcast, Pocket Casts, Podbean (https://pharmaphorum.podbean.com/) , and pretty much wherever else you download your other podcasts from.
Category
Oncology
Be the first to comment

Up Next